VIVS
VivoSim Labs, INC.
NASDAQ · Healthcare · Biotechnology · US
$0.16
+0.38%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.16
From 52W high−94.71%
Volume340889.00
Market cap$2.61M
P/E (TTM)—
P/S (TTM)23.3x
Div yield—
Key dataOct 19, 2026
Open
$0.16
From 52W high
−94.71%
Volume
340889.00
Market cap
$2.61M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
29.6
MomentumView details →
1D Return
+0.38%
YTD Return
−91.05%
SummaryUpdated Jun 1, 2026
VivoSim Labs, Inc. (NASDAQ:VIVS) is a biotechnology company founded in 2007 and headquartered in San Diego, California. The company went public in February 2012 and was formerly known as Organovo Holdings, Inc. before changing its name to VivoSim Labs in April 2025. VivoSim operates at the intersection of biotechnology and advanced manufacturing, developing innovative 3D tissue technologies for drug development and therapeutic applications. The company has evolved from a pure-play bioprinting technology provider to a clinical-stage biotechnology company with both platform technology offerings and proprietary drug candidates in development.
Similar companies
Latest newsMore news →
VivoSim Labs, INC. amended its lease with San Diego Inspire 2, LLC, surrendering Suite 202 effective February 28, 2027, extending the Suite 100 lease through April 30, 2028, setting monthly base rent at $43,072.85, and providing $86,145.70 in rent abatements.3d agoVivoSim Labs elected Adam Stern as a Class III director, effective September 30, 2026.13d agoVivoSim Labs elected Keith Murphy as a Class III director, effective September 30, 2026.13d ago